Bharat Biotech collaborates with Bilthoven Biologicals to strengthen global polio eradication
India’s Bharat Biotech (BBIL) and Bilthoven Biologicals (BBio), the Dutch subsidiary of the Serum Institute of India, have inked a pact to manufacture oral polio vaccines (OPVs) in India. Under an agreement, the vaccines will be produced in India utilizing drug substances supplied by the Dutch company.
Both entities will collaborate to secure the necessary regulatory approvals and licenses essential for the commercial production of OPVs in India. The manufactured vaccines will cater to both domestic and international markets.
Adar Poonawalla, chief executive of Serum Institute of India, emphasized the companies' shared vision of eradicating polio worldwide. This is a "crucial step towards reducing the impact of this deadly disease on vulnerable populations," he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze